Evidence map›Paper›PMID 37507428›Full record

ArticleScientific reports2023

Exploring ND-011992, a quinazoline-type inhibitor targeting quinone reductases and quinol oxidases.

Jan Kägi, Willough Sloan, Johannes Schimpf, Hamid R Nasiri, Dana Lashley, Thorsten Friedrich

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Carbon Monoxide and Prokaryotic Energy Metabolism.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jan KägiInstitut für Biochemie, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
Willough SloanDepartment of Chemistry, William & Mary, Williamsburg, VA, USA.
Johannes SchimpfInstitut für Biochemie, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
Hamid R NasiriDepartment of Cellular Microbiology, University Hohenheim, Stuttgart, Germany.ORCID 0000-0002-7265-2820
Dana LashleyDepartment of Chemistry, William & Mary, Williamsburg, VA, USA. dlashley@wm.edu.ORCID 0000-0002-0727-2442
Thorsten FriedrichInstitut für Biochemie, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany. Friedrich@bio.chemie.uni-freiburg.de.ORCID 0000-0002-0813-7883
University of Freiburg · DEWilliam & Mary · USUniversity of Hohenheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial energy metabolism has become a promising target for next-generation tuberculosis chemotherapy. One strategy to hamper ATP production is to inhibit the respiratory oxidases. The respiratory chain of Mycobacterium tuberculosis comprises a cytochrome bcc:aa

Indexed as

Escherichia coli ProteinsQuinone ReductasesCytochrome b GroupCytochromesElectron Transport Complex IElectron Transport Complex IVEscherichia coliHydroquinonesOxidoreductasesCytochrome b GroupCytochromesElectron Transport Complex IElectron Transport Complex IVEscherichia coli ProteinsHydroquinonesOxidoreductasesQuinone Reductases

Identifiers

PMID37507428
PMCPMC10382516
OpenAlexW4385349015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.